Kallyope
Kallyope is a biopharmaceutical company developing innovative medicines for migraine, with a lead asset in Phase 3.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Kallyope is a New York City-based company focused on big health challenges, particularly migraine. It leverages unique insights into neural signaling pathways to develop innovative medicines. Its lead asset, Elismetrep, is in Phase 3 for the acute treatment of migraine. The company was founded by world-leading neuroscientists and is staffed by experienced drug developers.
History
Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers. The company is based in New York City and focuses on developing innovative medicines for migraine.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/kallyope · Editorial policy · How profiles are compiled